| Autor: |
Raja Zaghlol, Amre Ghazzal, Sohab Radwan, Louay Zaghlol, Ahmad Hamad, Jiling Chou, Sara Ahmed, Mark Hofmeyer, Maria E. Rodrigo, Ajay Kadakkal, Phillip H. Lam, Sriram D. Rao, William S. Weintraub, Ezequiel J. Molina, Farooq H. Sheikh, Samer S. Najjar |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Journal of cardiac failure. 28(8) |
| ISSN: |
1532-8414 |
| Popis: |
Continuous infusion of ambulatory inotropic therapy (AIT) is increasingly used in patients with end-stage heart failure (HF). There is a paucity of data concerning the concomitant use of beta-blockers (BB) in these patients.We retrospectively reviewed all patients discharged from our institution on AIT. The cohort was stratified into 2 groups based on BB use. The 2 groups were compared for differences in hospitalizations due to HF, ventricular arrhythmias and ICD therapies (shock or antitachycardia pacing).Between 2010 and 2017, 349 patients were discharged on AIT (95% on milrinone); 74% were males with a mean age of 61 ± 14 years. BB were used in 195 (56%) patients, whereas 154 (44%) did not receive these medications. Patients in the BB group had longer duration of AIT support compared to those in the non-BB group (141 [1-2114] vs 68 [1-690] days). After adjusting for differences in baseline characteristics and indication for AIT, patients in the BB group had significantly lower rates of hospitalizations due to HF (hazard ratio [HR] 0.61 (0.43-0.86); P = 0.005), ventricular arrhythmias (HR 0.34 [0.15-0.74]; P = 0.007) and ICD therapies (HR 0.24 [0.07-0.79]; P = 0.02).In patients with end-stage HF on AIT, the use of BB with inotropes was associated with fewer hospitalizations due to HF and fewer ventricular arrhythmias. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect